RaghuramanS,ParkH,OsburnWO,WinkelsteinE,EdlinBR,RehermannB, 2012.Spontaneous clearance of chronic Hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion,J Infect Dis 205 763 -71
WilderJ,PatelK., 2014.A review of the natural history of chronic hepatitis C infection,North Am J Med Sci 7 1 -7
ZhuRX,SetoWK,LaiCL,YuenMF, 2016.Epidemiology of hepatocellular carcinoma in the Asia-Pacific Region,Gut Liver 10 332 -9
MichaelCK, 2014.Hepatocellular carcinoma: epidemiology and risk factors,J Hepatocell Carcinoma 1 115 -25
WestbrookRH,DusheikoG, 2014.Natural history of hepatitis C,J Hepatol 61 S58 -68
RazzaqZ,MalikA, 2014.Viral load is associated with abnormal serum levels of micronutrients and glutathione and glutathionedependent enzymes in genotype 3 HCV patients,BBA Clin 2 72 -8
Sosa-JuradoF,Hernández-GalindoVL,Meléndez-MenaD,Mendoza-TorresMA,Martínez-ArronizFJ,Vallejo-RuizV, 2014.Detection of hepatitis C virus RNA in saliva of patients with active infection not associated with periodontal or liver disease severity,BMC Infect Dis 14 72 -
MohamedAA,ElbedewyTA,El-SerafyM,El-ToukhyN,AhmedW,Ali El Din Z. Hepatitis C virus:, 2015.A global view,World J Hepatol 7 2676 -80
RingehanM,McKeatingJA,ProtzerU, 2017.Viral hepatitis and liver cancer,Philos Trans R Soc Lond B Biol Sci 20160274 -
de WeerdNA,NguyenT., 2012.The interferons and their receptorsdistribution and regulation,Immunol Cell Biol 90 483 -91
NagaokiY,ImamuraM,AikataH,DaijoK1,TeraokaY1,HondaF, 2017.The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy,PLoS One 12 e0182710d -
JiF,ZhangS,DengH, 2013.Efficacy of interferon-based antiviral therapy on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: Further evidence in decompensation cirrhosis,J Hepatol 58 1262 -4
CavalcanteLN,LyraAC, 2015.Predictive factors associated with hepatitis C antiviral therapy response,World J Hepatol 7 1617 -31
PolS,CorougeM,Vallet-PichardA, .Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life,Hepat Med 15. -
2018.Liver stiffness reduction correlates with histological characteristics of hepatitis C patients with sustained virological response,Liver Int 38 59 -67
GastroenterolRep, 2016., 4 24 -9
KanwalF,KramerJR,IlyasJ,DuanZ,El-SeragHB, 2014.HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of US. Veterans with HCV,Hepatology 60 98 -105
KanwalS,MahmoodT, 2014.Hepatitis C virus resistance to interferon therapy: an alarming situation,Cent Eur J Biol 9 1155 -67
BrjalinV.,HussainS,QureshiS,MalikSA,KazmiAR,NaeemM., 2012.Study of the effect of antiviral therapy on homocysteinemia in hepatitis C virus-infected patients,BMC Gastroenterol 12 117 -
DustinLB,CashmanSB,LaidlawSM, 2014.Immune control and failure in HCV infection-tipping the balance,J Leukoc Biol 96 535 -48
Interferon alpha (IFNα, 2016.-induced TRIM22 interrupts HCV replication by ubiquitinating NS5A,Cell Mol Immunol 13 94 -102
FrodshamAJ,ZhangL,DumpisU,TaibNA,BestS,DurhamA, 2006.Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence,Proc Natl Acad Sci USA 103 9148 -53
2013.peripheral type I interferon receptor correlated with oxidative stress in chronic hepatitis B virus infection,J Interferon Cytokine Res 33 405 -14
ChandraPK,GunduzF,HazariS,KurtR,PanigrahiR,PoatB, 2014.Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis,PLoS One 9 e108616 -
TaniguchiH,IwasakiY,TakahashiA,ShimomuraH,MoriyaA,YuPC, 2007.Intrahepatic mRNA levels of type I interferon receptor and interferon stimulated genes in genotype 1b chronic hepatitis C,Intervirology 50 32 -9
FriborgJ,LinB,ChenC, 2013.Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell lines,Virology 444 384 -93